Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N15/86—Viral vectors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/62—Insulins
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2740/00—Reverse transcribing RNA viruses
  • C12N2740/00011—Details
  • C12N2740/10011—Retroviridae
  • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
  • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
  • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2830/00—Vector systems having a special element relevant for transcription
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2830/00—Vector systems having a special element relevant for transcription
  • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2830/00—Vector systems having a special element relevant for transcription
  • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2830/00—Vector systems having a special element relevant for transcription
  • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
  • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Definitions

• the present invention relates to recombinant vectors of viral origin, the preparation of these vectors, the pharmaceutical compositions containing them and their therapeutic use, in particular in gene therapy and more particularly for the treatment and / or prevention of pathologies linked to hyperglycemia.
• Gene therapy consists of correcting a deficiency or an anomaly (mutation, aberrant expression, etc.) by introducing genetic information into the affected cell or organ.
• this genetic information can be introduced either in vitro into a cell extracted from the organ, the modified cell then being reintroduced into the organism, or directly in vivo into the appropriate tissue.
• Different techniques have been described for the introduction of this genetic information, among which various transfection techniques involving complexes of DNA and DEAE-dextran (Pagano et al., J. Virol.
• viruses as vectors for gene transfer has emerged as a promising alternative to these physical transfection techniques.
• different viruses have been tested for their ability to infect certain cell populations.
• retroviruses RSV, HMS, MMS, etc.
• the HSV virus adeno-associated viruses
• adenoviruses adenoviruses
• the present invention relates more particularly to the development of new viral vectors of particular interest for the treatment of pathologies linked to hyperglycaemia such as diabetes.
• Diabetes mellitus is a usually chronic syndrome, the most characteristic symptom of which is hyperglycemia causing, in the absence of elevation of the renal threshold for glucose, glycosuria. Its main cause is a deficiency, absolute or relative, insulin causing abnormalities not only of the metabolism of carbohydrates but also of those of proteins and fats.
• Diabetes is generally treated by administration of insulin, a treatment which is very restrictive for the patient.
• the object of the present invention is precisely to propose an original viral vector making it possible to compensate for this disorganization of glucose metabolism in an organism by restoring in a controlled manner a suitable concentration of insulin in vivo.
• glucose is a factor in regulating the transcription of genes in the majority of living beings. It has in particular been demonstrated that glucose is capable of stimulating the transcription of genes coding for glycolytic and lipogenic enzymes in hepatocytes and adipocytes such as for example the gene of pyruvate kinase type L, a tissue specific glycolytic enzyme which plays a role. determinant in the regulation of glycolysis and gluconeogenesis in the liver. The expression of the L-PK protein in the liver is under food and hormonal control. It is induced by a diet rich in glucose and on the contrary inhibited by deprivation and in diabetics.
• L-PK A. Kahn et al .; J. Mol. Biol. 209, (1989), 205-219).
• the element Ll a binding site for the nuclear factor 1 of hepatocytes (HNF1), the element L2, a binding site for nuclear factor 1 (NF1), the element L3, a binding site for nuclear factor 4 for hepatocytes (HNF 4) and the element L4, a site link for major late transcrpional factor (MLFT) / USF (see Figure 1).
• HNF1 nuclear factor 1 of hepatocytes
• NF1 nuclear factor 1
• HNF4 nuclear factor 4 for hepatocytes
• MLFT major late transcrpional factor
• the specific element of glucose / insulin response has been precisely located in the gene coding for L-PK, in the form of a perfect palindrome between nucleotides -168 to -144 from the cap site, ie in the element L4 (see figure 2).
• This IWRM has been shown to be able to confer a transcriptional response to glucose to a minimal promoter of L-PK consisting of the TATA box and of the element L1.
• the present invention relates to a defective recombinant virus comprising at least one heterologous gene under the control of an expression signal inducible by glucose or one of its analogs.
• glucose analog is meant to cover any compound having structural homologies with glucose and being capable of inducing activation of the expression signal.
• analogs capable of being used according to the present invention mention may in particular be made of fructose, galactose, sucrose, lactose and all the sugars which can be hydrolyzed into these substances.
• a glucose-inducible expression signal covers any expression signal sequence whose activation, which conditions the subsequent transcription of the associated heterologous gene, is essentially induced in the presence of glucose or one of its analogs.
• the expression signal is placed under the control of an expression signal derived in whole or in part from the promoter of the gene coding for the pyruvate kinase of type L, L-PK. More specifically, this expression signal derives in whole or in part from the fragment consisting of 183 bp located 5 ′ from the coding phase of the gene coding for L-PK.
• the expression signal according to the invention comprises all or part of the sequence SEQ ID No. 1.
• this expression signal comprises at least all or part of the L4 element of this promoter.
• the element L4 is preferably represented by all or part of the sequence
• SEQ ID No. 2 of a sequence hybridizing with all or part thereof or of a sequence derived therefrom, and capable of interacting with the factor MLTF USF.
• the term “derivative” means any sequence obtained by one or more modifications and retaining at least one of the biological properties of the original sequence and in particular its ability to interact with its factor (s) ) specific binding (s), in this case constituted by the factor MLTF USF.
• Modification means any mutation, substitution, deletion, addition or modification of a genetic and / or chemical nature. These modifications can be carried out by techniques known to those skilled in the art.
• the element L4 is repeated in the form of 4 successive oligomers in the expression signal.
• the expression signal comprises, in addition to the L4 element, all or part of the L3 element of the promoter of the gene coding for L-PK.
• the element L3 is preferably represented in whole or in part by the sequence SEQ ID NO: 1
• the expression signal comprises the element L4 of the promoter of the gene coding for L-PK, fused upstream of the element L3 of this same promoter. It is then designated by L4-L3. More preferably, the expression signal according to the invention comprises 4 successive L4-L3 oligomers.
• This expression signal also comprises a so-called minimal promoter.
• minimal promoter designates any promoter sequence which alone is not capable of efficiently ensuring the transcription of the heterologous sequence which is associated with it.
• the activity of such a promoter turns out to be totally dependent on the activation of the element responding to glucose.
• this minimal promoter mainly has the function of directing transcription. In this perspective, it is preferably located upstream of the heterologous sequence so as to form with it a continuous nucleotide sequence.
• a minimal promoter deriving from a conventional promoter such as for example those activating the transcription of gene of thymidine kinase, acetyl transferase chloramphenicol, ⁇ galactosidase or luciferase type or in particular deriving from the promoter of the gene coding for pyruvate kinase type L.
• This minimal promoter can also be derived from human CMV. If necessary, such a promoter can be minimized by means of one or more genetic mutations which render it incapable of ensuring the transcription of the heterologous gene alone.
• the minimal promoter can derive from the promoter naturally responsible for the expression of the heterologous gene considered.
• a minimal promoter capable of being used according to the invention one can more particularly cite the sequence corresponding to the fragment - 119 to 11 located 5 ′ of the gene coding for L-PK.
• this minimal promoter is placed upstream of the nucleic sequence whose expression it controls, in substitution or not for its natural promoter.
• the promoter of the nucleic acid sequence can in fact remain present but in an inactivated form or made non-functional by various techniques known to those skilled in the art and in particular by deletion, deletion and / or addition of one or more bases.
• the expression signal responds in whole or in part to SEQ ID No. 4 or one of its derivatives.
• the promoter region can be modified by adding activation or regulation sequences (enhancer sequences in particular), making it possible to increase the strength of the promoter without affecting its inducible nature.
• activation or regulation sequences in particular
• SEQ ID No. 6 corresponding to nucleotides 1915 to 2379.
• heterologous nucleic acid sequence placed under the control of the expression signal comprises one or more therapeutic genes whose transfer and / or expression in a cell, an organ or an organism is research.
• the therapeutic genes which can thus be transferred are any gene whose transcription and possibly translation into the target cell generate products having a therapeutic effect.
• the protein product thus coded can be a protein, a peptide, an amino acid, etc.
• This protein product can be homologous with respect to target cell (i.e. a product which is normally expressed in the target cell when the latter presents no pathology).
• target cell i.e. a product which is normally expressed in the target cell when the latter presents no pathology.
• the expression of a protein makes it possible for example to compensate for an insufficient expression in the cell or the expression of an inactive or weakly active protein due to a modification, or else to overexpress said protein.
• the therapeutic gene can also code for a mutant of a cellular protein, having increased stability, modified activity, etc.
• the protein product can also be heterologous towards the target cell.
• an expressed protein can for example supplement or provide a deficient activity in the cell allowing it to fight against a pathology.
• trophic factors BDNF, CNTF, NGF, IGF, GMF, aFGF, bFGF, NT3, NT5, etc; apolipoproteins: ApoAI, ApoAIV, ApoE, etc. (FR 93 05125), dystrophin or a minidystrophin (FR 91 11947), etc.
• the heterologous sequence comprises at least one gene coding for insulin or a variant of insulin.
• variant notably covers the various forms of maturation of insulin such as, for example, proinsulin, (Vollenweider et al., J. Biol. Chem. 267, (1992) 14629-14636 and Groskreutz et al. , J. Biol. Chem. 269, (1994), 6241-6245).
• the gene coding for insulin and present in a vector according to the invention comprises all or part of the sequence SEQ ID No. 5.
• the vectors of the invention can be prepared from different types of virus.
• vectors derived from adenoviruses or retroviruses are used.
• the viruses according to the invention are defective, that is to say that they are unable to replicate autonomously in the target cell.
• the genome of the defective viruses used in the context of the present invention is therefore devoid of at least the sequences n-necessary for the replication of said virus in the infected cell. These regions can be either eliminated (in whole or in part), or made non-functional, or substituted by other sequences and in particular by the DNA sequence coding for the gene of interest such as that of insulin .
• the defective virus nevertheless retains the sequences of its genome which are necessary for the packaging of the viral particles.
• adenoviruses As regards more particularly adenoviruses, different serotypes, whose structure and properties vary somewhat, have been characterized. Among these serotypes, it is preferred to use, within the framework of the present invention, human adenoviruses of type 2 or 5 (Ad 2 or Ad 5) or adenoviruses of animal origin (see application FR 93 05954).
• adenoviruses of animal origin which can be used in the context of the present invention, mention may be made of adenoviruses of canine, bovine, murine origin (example: Mavl, Beard et al., Virology 75 (1990) 81), ovine, porcine , avian or even simian (example: after-sales service).
• the adenovirus of animal origin is a canine adenovirus, more preferably a CAV2 adenovirus [Manhattan strain or A26 / 61 (ATCC VR-800) for example].
• adenoviruses of human or canine or mixed origin are used.
• the defective adenoviruses of the invention comprise ITRs, a sequence allowing the packaging and the sequence coding for the protein of therapeutic interest.
• the El gene and at least one of the E2, E4, L1-L5 genes are non-functional.
• the viral gene considered can be made non-functional by any technique known to those skilled in the art, and in particular by total suppression, substitution, partial deletion, or addition of one or more bases in the gene or genes considered. Such modifications can be obtained in vitro (on isolated DNA) or in situ, for example, using genetic engineering techniques, or by treatment with mutagenic agents.
• the defective recombinant adenoviruses according to the invention can be prepared by any technique known to those skilled in the art (Levrero et al., Gene 101 (1991) 195, EP 185 573; Graham, EMBO J. 3 (1984) 2917).
• retroviruses are integrative viruses, selectively infecting dividing cells.
• the genome of retroviruses essentially comprises two LTRs, an encapsidation sequence and three coding regions (gag, pol and env).
• the gag, pol and env genes are generally deleted, in whole or in part, and replaced by a heterologous nucleic acid sequence of interest.
• These vectors can be produced from different types of retroviruses such as in particular MoMuLV ("murine moloney leukemia virus”; also designated MoMLV), MSV ("murine moloney sarcoma virus"), HaSV ("harvey sarcoma virus”) ; SNV (“spleen necrosis virus”); RSV ("rous sarcoma virus”) or the Friend virus.
• the packaging sequence and said sequence of interest is generally constructed, then used to transfect a cell line called packaging, capable of providing in trans retroviral functions deficient in the plasmid.
• packaging lines are therefore capable of expressing the gag, pol and env genes.
• packaging lines have been described in the prior art, and in particular the line PA317 (US4,861,719); the PsiCRIP line (WO90 / 02806) and the GP + envAm-12 line (WO89 / 07150).
• the ⁇ -2 cell line which comes from the NIH-3T3 line (mouse fibroblastic line) by transfection with pMOV- ⁇ " , a plasmid containing the genome of the Moloney murine leukemia virus (MoMuLV) whose packaging sequence" ⁇ "is deleted (Mann et al., Cell, (1983), 33, 153-
• the recombinant retroviruses may include modifications at the level of the LTRs to suppress transcriptional activity, as well as extended packaging sequences comprising a part of the gag gene (Bender et al., J. Viral. (1987) 61, 1639) The recombinant retroviruses produced are then purified by conventional techniques.
• the retroviruses can be prepared by transfection of a retroviral plasmid containing the expression signal according to the invention coupled to the gene coding for the protein of interest in a transcomplementing cell line which will make it possible to produce viral particles whose genome codes for the transgene.
• the retrovirus being very particularly advantageous for expressing insulin.
• the expression of the gene coding for insulin under the control of an expression signal controlled by glucose and by transfecting cells in vivo using this type of vector these cells are induced to produce insulin under the effect of their physiological glucose content. These cells become capable of expressing the insulin transgene in the presence of a physiological and sufficient concentration of glucose.
• the transfected cells have an internal glucose detection system, also designated by glucose sensor machinery, capable of inducing the activation of the expression signal.
• glucose detection system also designated by glucose sensor machinery
• Certain cell types, such as hepatocytes and ⁇ cells of the pancreas are naturally provided with it. It is a system notably composed of specific enzymes such as the Glut-2-glucose transporter and glucokinase. As for cells deprived of this type of sensory machinery, it is entirely possible to supply them artificially.
• the cells to be treated are, either prior to or simultaneously with the injection of virus according to the invention, transfected using genetic constructs controlling the synthesis of the Glut-2 transporter of the enzyme glucokinase.
• Infection of cells such as hepatocytes with recombinant viruses according to the invention can be carried out ex vivo and / or in vivo making the cells thus transfected capable of secreting insulin.
• the preferred infection sites in the context of the present invention are the natural sites of insulin secretion, such as the portal vein.
• the present invention also relates to mammalian cells, preferably human and more preferably to hepatocytes and / or pancreatic ⁇ cells infected with one or more viruses claimed.
• the vectors according to the invention advantageously allow the immediate blocking of this secretion under the effect of glucagon due to the classic AMP. This eliminates the risk of hypoglycemia induced by excessive insulin secretion.
• the claimed vectors are particularly advantageous for controlling in vivo via a phenomenon of glucose induction, the production of insulin in a precise region of the organism, preferably in a site where it is normally secreted like the circulating portal .
• Cells infected with one or more of the claimed viruses could thus be implanted in the liver, spleen, pancreas or intestine.
• the present invention thus describes a new approach for the treatment in particular of insulin-dependent diabetic disorders consisting in inducing in vivo synthesis of insulin in response to a physiological glucose content.
• the concentration of glucose or of an analog having the same influence on the glucose response sequence would be there adjusted so as to induce the expression of the protein of interest via the activity of the expression signal according to the invention. It is clear that this concentration is determined according to the quantity of vectors injected, the nature of the site of infection and the desired expression of protein.
• the present invention also relates to any use of a virus as described above for the preparation of a pharmaceutical composition in particular intended for the treatment and / or prevention of diseases linked to hyperglycemia.
• the present invention also relates to a pharmaceutical composition
• a pharmaceutical composition comprising one or more defective recombinant viruses as described above.
• These pharmaceutical compositions can be formulated for topical, oral, parenteral, intranasal, intravenous, intramuscular, subcutaneous, intraocular, transdermal, etc. administration.
• the pharmaceutical compositions of the invention contain a pharmaceutically acceptable vehicle for an injectable formulation. They may in particular be sterile, isotonic solutions, or dry compositions, in particular lyophilized, which, by addition as appropriate of sterilized water or physiological saline, allow the constitution of injectable solutes.
• the doses of defective recombinant virus used for injection can be adapted as a function of various parameters, and in particular as a function of the viral vector, of the mode of administration used, of the pathology concerned or also of the duration of the treatment sought.
• the recombinant viruses according to the invention are formulated and administered in the form of doses of between 10 ⁇ and 10 ⁇ 4 pfu / ml, and preferably 10 ⁇ to 10 * 0 pfu / ml.
• the term pfu (“plaque forming unit”) corresponds to the infectious power of a virus solution, and is determined by infection of an appropriate cell culture, and measurement, generally after 48 hours, the number of ranges of infected cells. The techniques for determining the pfu titer of a viral solution are well documented in the literature.
• the compositions according to the invention can directly comprise the producer cells, with a view to their implantation.
• Figure 1 Schematic representation of the order of succession of elements L1 to L4 identified in the promoter of the L-PK gene and their respective binding proteins.
• Figure 2 Representation of the palindrome of element L4.
• Figure 3 Partial representation of the retroviral plasmid pHSG (L4L3) 4PKCAT and clones F6 and B8.
• Figure 4 Quantitative determination of CAT activity in mhATTIIF cells transformed with the clone B8, as a function of the amount of glucose injected.
• Figure 5 Quantitative determination of CAT activity in mhATIIIF cells transformed with clone B8 at different induction times.
• Figure 6 Construction of pHSG / PK-CAT and pHSG / AL-PK-CAT plamids.
• Figure 7 Induction by glucose at different doses of the expression of the plasmids pHSG / PK-CAT and pHSG / AL-PK-CAT.
• the plasmids of the pBR322, pUC type and the phages of the Ml 3 series are of commercial origin (Bethesda Research Laboratories).
• the DNA fragments can be separated according to their size by electrophoresis in agarose or acrylamide gels, extracted with phenol or with a phenol / chloroform mixture, precipitated with ethanol and then incubated in the presence of the DNA ligase from phage T4 (Biolabs) according to the supplier's recommendations.
• the destruction of the protruding 3 ′ ends is carried out in the presence of the DNA polymerase of phage T4 (Biolabs) used according to the manufacturer's recommendations.
• the destruction of the protruding 5 ′ ends is carried out by gentle treatment with nuclease SI.
• Mutagenesis directed in vitro by synthetic oligodeoxynucleotides can be carried out according to the method developed by Taylor et al. [Nucleic Acids Res. 13. (1985) 8749-8764] using the kit distributed by Amersham.
• Verification of the nucleotide sequences can be carried out by the method developed by Sanger et al. [Proc. Natl. Acad. Sci. USA, 2 ⁇ (1977) 5463-5467] using the kit distributed by Amersham.
• All plasmids are constructed using standard DNA cloning techniques. The junctions are verified by DNA sequencing.
• the construction of the plasmid pHSG (L4L3) 4-PKCAT, (represented in FIG. 3), contains the constructive part MMLV of pHSGNeo and the coding sequence for the CAT gene under the control of the promoter of the rat type L pyruvate kinase gene (bp - 119 to + 11) upstream of which L4L3 fragments oligomerized 4 times (ie the IWRM and the contiguous HNF4 binding site) are ligated.
• the L4L3 fragment corresponding to the fragment delimited between bp -172 to- 123, upstream of the site of initiation of L-PK transcription was obtained by PCR.
• the polyA signal sequence used is that present in the LTR of the 3 'end of MMLV.
• the plasmid pHSGNeo (Guild et al. J. Virol. 1988, 62, 3795-3801), a retroviral plasmid derived from MMLV, the psi-CRIP line, a complementary amphotropic cell line which provides trans structural proteins of MMLV, have were provided by Dr. A. Weber (Cochin Institute of Molecular Genetics, Paris); the plasmid pRSVNeo, in which the aminoglycoside phosphotransferase gene is under the control of the RSV LTR promoter, is used for cotransfection.
• the cell line mhATIIIF is derived from a liver tumor in a transgenic mouse expressing the early SV40 genes under the control of the liver-specific antithrombin III promoter, (ATIII-SV40) (Kahn A. et al. Exp; Cell. Res;
• MIX (1: 1 vol / vol) with glutamax-1 or DMEM / HamF12 (1: 1 vol / vol) (Gibco- BRL) with or without D + glucose (Sigma), supplemented with 1 ⁇ M dexamethasone, 1 ⁇ M triodothyronine, 20 nM human insulin, 5% (vol / vol) of FCS.
• the NIH3T3 and psi-CRIP cells are cultured in: DMEM (5.5 mM of glucose, l.OmM sodium pyruvate) supplemented with 10% (vol / vol) of newborn calf serum. Ampicillin, streptomycin and glutamine are added to all the media and the cultures are incubated at 37 ° C.
• the psi-CRIP cells are cotransfected with the plasmids pHSG (L3L4) 4- PKCAT and pRSV Neo (the molar ratio of the two plamisdes being 10: 1) by the cationic liposome method (DOTAP, Boeringer Mannheim) and selected in the presence of G418 (800 ⁇ g ml).
• the clones resistant to G418 are separated for the test of production of the retroviruses.
• the cell clones resistant to G418 are seeded in 90 mm wells and cultured up to 100% confluence.
• the cell culture supernatant is filtered through a membrane having pores of 0.22 ⁇ m, incubated with DNase I (10 ⁇ g / ml) at 37 ° C for 30 min and then centrifuged at 65,000 rpm for 20 minutes at 4 ° C .
• the retroviral RNA is extracted and purified from precipitation pellets by proteinase K and a phenol / chloroform mixture then co-precipitated with t RNA.
• the sample is dissolved in diethyl pyrocarbonate treated with water and containing 1 mM of dithiothreitol (DTT), 40 U of RNAsin / 100 ⁇ m, then subjected to reverse transcriptase and to PCR in a single step.
• DTT dithiothreitol
• - 5 'TCAACGGTGGTATATCCAGAT 3' (SEQ ID No. 8), corresponding to the coding region of the CAT gene (bp 35 to 15 considering the site of initiation of translation).
• Reverse transcription from the antisense PCR probe is catalyzed by 8U AMV reverse transcriptase (Promega) for 1 hour at 42 ° C and the following PCR with Taq25U DNA polymerase is carried out in 35 to 40 cycles.
• the expected amplified fragment is 440 bp long and contains part of the gag gene, 4 repeat motifs L3L4, the -119 L-PK promoter and the first 69 bp of the CAT gene. If necessary, the RT-PCR fragments are cloned and sequenced.
• the retroviral vectors pHSG (L4L3) 4-119PKCAT and pRSVNeo are used to co-transfect psi-CRIP cell lines. 70 clones resistant to G418 are analyzed. 8 positive RT-PCR clones demonstrate an ability to produce infectious recombinant retroviruses, determined by PCR specific for the expected fragment of the genomic DNA of NIH3T3 cells. The production of retrovirus has been demonstrated to be significant in two clones.
• the clone F6 (5.10 ⁇ ) infectious retrovirus, produces a retrovirus with the complete region of the signal sequence (4 repetitions of the whole L4L3 fragments (see FIG. 3)) and
• the retrovirus titers were estimated by semiquantitative PCR-RT using different deletions in pHSG (L4L3) 4199PKCAT as standards.
• Positive clones are used to infect NIH3T3 cells in order to estimate the infectious capacities of the retroviruses produced.
• 1 ml of cell culture supernatant at 100% confluence is used to infect NIH3T3 cells growing logarithmically with 8 ⁇ g / ml of polybrene. After 3 hours of incubation, the polybrene is diluted to 2 ⁇ g ml with medium and the culture is continued for 48 hours.
• the genomic DNA of the infected NIH3T3 cells is extracted and used for PCR amplification using the probes described in example 3. The detection of the specific amplified fragment proves the integration of the retroviral sequences in the genome of the infected cells.
• the titer is estimated by comparing the intensities of the amplified DNA bands from the genomic DNA of the infected cells with those from different dilutions of the retrovirus (10 ⁇ to 10 ⁇ molecules).
• the clones which produce infectious retroviruses are co-cultivated with mhATIIIF cells according to the following protocol:
• the small well is removed.
• the medium is changed for a further 16 hour incubation, the polybrene is then added (8 ⁇ g) and the cells are cultured for 48 hours.
• the mhATIIIF cell line assimilable to hepatocytes in rats retains its ability to respond to glucose by transcriptional activation of the L-PK gene and is therefore suitable for testing the response of the CAT transgene, transferred by the retroviral vector and consequently the activity of the L-PK IWRM in a retroviral environment.
• the mhATIIIF cells are cultured twice with cells producing the retroviruses, which leads to a satisfactory infection rate with the clone B8.
• the expression of the L-PK / CAT transgene in infected mhATIIIF cells is well induced by glucose with half of the maximum induction obtained for 3-4 mM of glucose and the induction maximum for 8mM glucose.
• the CAT activity remains relatively stable.
• MhATIIIF the cells are cultured in a medium containing 17 mM glucose, induction of the gene is observed from the 8 ⁇ I hour of incubation, induction to half before the 24th hour and maximal induction at the 48 ⁇ me time.
• Plasmids are constructed using standard DNA cloning techniques. The junctions are verified by DNA sequencing.
• the construction of the plasmid pHSG / PK-CAT contains the MMLV part of pHSG located between the nucleotides from 1 to 2015 and from 3888 to 4445; for the plasmid pHSG / AL-PK-CAT, the MMLV sequences are located between the nucleotides from 1 to 2015 and from 4290 to 4847 (FIG. 6).
• sequence coding for the CAT gene under the control of the promoter of the rat type L pryruvate kinase gene (-183 to + 11 bp) is located between nucleotides 2048 and 3033 for the plasmid pHSG / PK-CAT and between 2450 and 3435 for the plasmid pHSG / AL-PK-CAT.
• sequence of the enhancer fragment of the aldolase B gene (SEQ ID No. 6), is located between nucleotides 2035 and 2437 in the plasmid pHSG / AL-PK-CAT.
• the poly A signal sequence used is that of SV40 located between nucleotides 3033 and 3873 in pHSG / PK-CAT and between 3435 and 4275 in pHSG / AL-PK-CAT.
• Nucleotides from 2015 to 2048; 2242 to 2452 and 3873 to 3888 are adapters between the different fragments for the plasmid pHSG / PK-CAT; they are located for the plasmid pHSG / AL-PK-CAT from 2015 to 2035; 2437 to 2450; 26-44 to 2654 and 4275 to 4290.
• EXAMPLE 8 Induction by Glucose at Different Doses of the Expression of the Plasmids pHSG / PK-CAT and pHSG / AL-PK-CAT
• the cell line mhAT3F originates from a liver tumor in a transgenic mouse expressing the pre-exposed SV40 genes under the control of the liver-specific antithrombin III promoter (Kahn A. et al. Exp; Cell.Res; 200, 175-185) . These cells were cultured at 37 ° C. with 5% (vol / vol) CO2 in a DMEM F12 / NUT.MIX nutrient medium. (1: 1 vol / vol) with glutamax-1 (Gibco-BRL) with or without D-glucose (Sigma), supplemented with 1 ⁇ M dexamethasone, 1 ⁇ M triodothyronine and 20 nM human insulin.
• the expression of the plasmid pHSG / PK-L in the presence of the enhancer of aldolase B is 5 times stronger in the presence 8 mM glucose than that of the plasmid lacking the aldolase B enhancer (FIG. 7).
• This hybrid aldolase B / PK-L promoter is therefore particularly advantageous for conferring on a gene a high level of expression while remaining sensitive to glucose, in particular within the framework of the development of a gene therapy method for diabetes intended to produce, depending blood sugar, a suitable in vivo insulin concentration.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Genetics & Genomics (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Zoology (AREA)
• Biotechnology (AREA)
• Wood Science & Technology (AREA)
• Biomedical Technology (AREA)
• General Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Microbiology (AREA)
• Biophysics (AREA)
• Diabetes (AREA)
• Plant Pathology (AREA)
• Medicinal Chemistry (AREA)
• Physics & Mathematics (AREA)
• Virology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Endocrinology (AREA)
• Animal Behavior & Ethology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Obesity (AREA)
• Hematology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Emergency Medicine (AREA)
• Gastroenterology & Hepatology (AREA)
• Toxicology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Immunology (AREA)
• Epidemiology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=9478162

Family Applications (1)

Country Status (14)

Families Citing this family (10)

Family Cites Families (4)

• 1995
  • 1995-04-14 FR FR9504558A patent/FR2732978B1/fr not_active Expired - Fee Related
• 1996
  • 1996-04-12 CA CA002215987A patent/CA2215987A1/fr not_active Abandoned
  • 1996-04-12 MX MX9707910A patent/MX9707910A/es not_active IP Right Cessation
  • 1996-04-12 AU AU56523/96A patent/AU715377B2/en not_active Ceased
  • 1996-04-12 CZ CZ19973251A patent/CZ292564B6/cs not_active IP Right Cessation
  • 1996-04-12 SK SK1377-97A patent/SK137797A3/sk unknown
  • 1996-04-12 WO PCT/FR1996/000560 patent/WO1996032489A1/fr not_active Application Discontinuation
  • 1996-04-12 HU HU9802587A patent/HUP9802587A3/hu unknown
  • 1996-04-12 US US08/945,140 patent/US6309878B1/en not_active Expired - Fee Related
  • 1996-04-12 BR BR9604938A patent/BR9604938A/pt not_active Application Discontinuation
  • 1996-04-12 EP EP96913579A patent/EP0821741A1/de not_active Withdrawn
  • 1996-04-12 JP JP8530778A patent/JPH11503608A/ja not_active Withdrawn
  • 1996-04-12 KR KR1019970707243A patent/KR19980703843A/ko not_active Application Discontinuation
• 1997
  • 1997-10-13 NO NO974726A patent/NO974726D0/no not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events